HighTower Advisors’s Avadel Pharmaceuticals AVDL Stock Holding History

HighTower Advisors’s Portfolio AVDL Stock Details AVDL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-15,209	Closed	-$328K	–	3808
2025 Q4	$328K	Buy	15,209 +4,823	+46%	+$93.6K	﹤0.01%	2973
2025 Q3	$159K	Buy	+10,386	New	+$135K	﹤0.01%	3436
2025 Q1	–	Sell	-6,786	Closed	-$71.3K	–	3758
2024 Q4	$71.3K	Sell	6,786 -714	-10%	-$8.67K	﹤0.01%	3423
2024 Q3	$98K	Buy	+7,500	New	+$114K	﹤0.01%	3317

Other funds holding AVDL

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

HNB

Huntington National Bank Columbus, Ohio $20.6B AUM 34.61% 1-Year Est. Return

HighTower Advisors's AVDL Position: Q1 2026 in Review

HighTower Advisors sold out of Avadel Pharmaceuticals (AVDL) in Q1 2026, closing a stake of 15,209 shares — an estimated $328K sold.

HighTower Advisors first reported a position in AVDL in Q3 2024 and held it in 4 quarters. The position peaked at $328K in Q4 2025. 2 funds tracked by Wall St. Rank hold AVDL as of Q1 2026.

HighTower Advisors reported no remaining Avadel Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
HighTower Advisors sold 15,209 Avadel Pharmaceuticals shares in Q1 2026, an estimated $328K.
HighTower Advisors first reported a position in Avadel Pharmaceuticals in Q3 2024 and held it in 4 quarters.
HighTower Advisors's Avadel Pharmaceuticals position peaked at $328K in Q4 2025.
2 funds tracked by Wall St. Rank held Avadel Pharmaceuticals as of Q1 2026.

Based on HighTower Advisors's 13F filing for Q1 2026, filed 5 May 2026.